ZLAB vs. VKTX, ITCI, JAZZ, BPMC, IONS, OGN, BBIO, CYTK, APLS, and MDGL
Should you be buying Zai Lab stock or one of its competitors? The main competitors of Zai Lab include Viking Therapeutics (VKTX), Intra-Cellular Therapies (ITCI), Jazz Pharmaceuticals (JAZZ), Blueprint Medicines (BPMC), Ionis Pharmaceuticals (IONS), Organon & Co. (OGN), BridgeBio Pharma (BBIO), Cytokinetics (CYTK), Apellis Pharmaceuticals (APLS), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "pharmaceutical preparations" industry.
Zai Lab (NASDAQ:ZLAB) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, community ranking, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.
Viking Therapeutics received 379 more outperform votes than Zai Lab when rated by MarketBeat users. Likewise, 79.87% of users gave Viking Therapeutics an outperform vote while only 63.58% of users gave Zai Lab an outperform vote.
In the previous week, Viking Therapeutics had 9 more articles in the media than Zai Lab. MarketBeat recorded 13 mentions for Viking Therapeutics and 4 mentions for Zai Lab. Viking Therapeutics' average media sentiment score of 1.06 beat Zai Lab's score of 0.56 indicating that Viking Therapeutics is being referred to more favorably in the news media.
Zai Lab presently has a consensus target price of $64.22, indicating a potential upside of 247.91%. Viking Therapeutics has a consensus target price of $112.38, indicating a potential upside of 71.93%. Given Zai Lab's higher possible upside, research analysts plainly believe Zai Lab is more favorable than Viking Therapeutics.
Zai Lab has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.
41.7% of Zai Lab shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 5.2% of Zai Lab shares are held by insiders. Comparatively, 4.7% of Viking Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Viking Therapeutics has a net margin of 0.00% compared to Zai Lab's net margin of -116.45%. Viking Therapeutics' return on equity of -18.41% beat Zai Lab's return on equity.
Viking Therapeutics has lower revenue, but higher earnings than Zai Lab. Viking Therapeutics is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.
Summary
Viking Therapeutics beats Zai Lab on 14 of the 18 factors compared between the two stocks.
Get Zai Lab News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZLAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
